Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
2.
J Hosp Infect ; 97(4): 363-370, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28939316

ABSTRACT

BACKGROUND: Multidrug-resistant Candida auris infection has been reported from five continents in recent years. The prevalence of C. auris invasive infection has been estimated at 5.3% for intensive-care-acquired candidaemia in India. The transmission of the organism between the patients and from environment to patients is rapid. AIM: To understand the intra-hospital dynamics of C. auris transmission and to determine the possible interventions to prevent its spread. METHODS: Surveillance of intensive care units was carried out to assess patient colonization, environmental contamination and hand carriage of the yeast among healthcare workers. Interventions including chlorhexidine washing of patients and decontamination of environmental surfaces with stabilized hydrogen peroxide disinfectant (Ecoshield) were undertaken. We further evaluated the effectiveness of frequently used disinfectants in the hospital against C. auris on various inanimate surfaces, and its persistence on hospital fabrics. FINDINGS: Three cases of C. auris bloodstream infection were detected over a period of three months. Many patients admitted at the same time, in the same area, were colonized by C. auris. Surveillance detected C. auris contamination of environmental surfaces and hands of healthcare workers. Interventions such as chlorhexidine washing and appropriate use of disinfectants could eradicate C. auris from patients and hospital environment. CONCLUSION: The frequently used disinfectants in our hospital and current hand hygiene practices were efficient against C. auris if proper contact time and procedures were followed. Evaluation of possible persistence of C. auris on dry fabrics showed that they can persist for up to seven days.


Subject(s)
Candida/isolation & purification , Candidiasis, Invasive/epidemiology , Cross Infection/epidemiology , Disease Outbreaks , Disease Transmission, Infectious/prevention & control , Infection Control/methods , Aged , Candidiasis, Invasive/microbiology , Candidiasis, Invasive/transmission , Cross Infection/microbiology , Cross Infection/transmission , Disinfectants/administration & dosage , Environmental Microbiology , Female , Follow-Up Studies , Hand/microbiology , Humans , India , Male , Middle Aged , Young Adult
3.
Intensive Care Med ; 40(10): 1429-48, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24934813

ABSTRACT

INTRODUCTION: For decades, clinicians dealing with immunocompromised and critically ill patients have perceived a link between Candida colonization and subsequent infection. However, the pathophysiological progression from colonization to infection was clearly established only through the formal description of the colonization index (CI) in critically ill patients. Unfortunately, the literature reflects intense confusion about the pathophysiology of invasive candidiasis and specific associated risk factors. METHODS: We review the contribution of the CI in the field of Candida infection and its development in the 20 years following its original description in 1994. The development of the CI enabled an improved understanding of the pathogenesis of invasive candidiasis and the use of targeted empirical antifungal therapy in subgroups of patients at increased risk for infection. RESULTS: The recognition of specific characteristics among underlying conditions, such as neutropenia, solid organ transplantation, and surgical and nonsurgical critical illness, has enabled the description of distinct epidemiological patterns in the development of invasive candidiasis. CONCLUSIONS: Despite its limited bedside practicality and before confirmation of potentially more accurate predictors, such as specific biomarkers, the CI remains an important way to characterize the dynamics of colonization, which increases early in patients who develop invasive candidiasis.


Subject(s)
Candida albicans/growth & development , Candidiasis/physiopathology , Critical Illness , Cross Infection/microbiology , Immunocompromised Host , Antifungal Agents/administration & dosage , Candida albicans/drug effects , Candida albicans/isolation & purification , Candidiasis/epidemiology , Candidiasis/prevention & control , Candidiasis/transmission , Candidiasis, Invasive/epidemiology , Candidiasis, Invasive/physiopathology , Candidiasis, Invasive/prevention & control , Candidiasis, Invasive/transmission , Chemoprevention , Cross Infection/epidemiology , Cross Infection/prevention & control , Cross Infection/transmission , Humans , Intensive Care Units/statistics & numerical data , Risk Factors
4.
Expert Rev Anti Infect Ther ; 11(7): 709-21, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23829639

ABSTRACT

Invasive fungal infections due to Candida are the third most common late-onset infection in infants born with birth weight <1500 g. Invasive candidiasis in infants born with birth weight <1000 g is associated with a 30% mortality and with neurodevelopmental impairment in more than half the survivors. A high degree of suspicion and a thorough multisystem evaluation is necessary for diagnosis of invasive fungal infections and to detect complications or sequalae. Amphotericin B deoxycholate is the mainstay in the treatment of invasive fungal infections in newborns. Early initiation of enteral feeds with human milk, decreasing dependence on catheters and avoidance of antacids, steroids and broad-spectrum antibiotics are the recommended preventive measures. Fluconazole prophylaxis should be targeted towards neonates born with <1000 g in neonatal units where baseline rates of invasive candidiasis are more than 5%.


Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Candidiasis, Invasive/drug therapy , Deoxycholic Acid/therapeutic use , Amphotericin B/adverse effects , Antifungal Agents/adverse effects , Candidiasis, Invasive/epidemiology , Candidiasis, Invasive/transmission , Deoxycholic Acid/adverse effects , Drug Combinations , Drug Therapy, Combination , Echinocandins/chemistry , Echinocandins/therapeutic use , Humans , Infant, Low Birth Weight , Infant, Newborn , Nucleosides/chemistry , Nucleosides/therapeutic use , Risk Factors , Triazoles/therapeutic use
5.
Enferm Infecc Microbiol Clin ; 30(10): 645-53, 2012 Dec.
Article in Spanish | MEDLINE | ID: mdl-23127517

ABSTRACT

Invasive fungal infections (IFI) represent a serious threat for patients undergoing solid organ transplantation (SOT). IFI in SOT has a significant incidence and mortality not due to negligence. The management of IFI in SOT involves specific recommendations and has been individualized to the type of transplant and patient. The current review presents an overview of epidemiology, diagnosis, treatment and prevention of IFI in TOS. Depending on risk factors for different IFIs and transplant type, this paper includes the main recommendations based on previous publications and on the opinion of the authors on the prophylaxis and treatment of these patients. These recommendations highlight epidemiology changes and the emergence of new antifungals. The current document has focused mainly on Candidaspp. and Aspergillusspp., with a special mention to the rest of yeasts and moulds that are common in SOT.


Subject(s)
Fungemia/etiology , Organ Transplantation , Postoperative Complications/etiology , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Aspergillosis/diagnosis , Aspergillosis/drug therapy , Aspergillosis/epidemiology , Aspergillosis/etiology , Aspergillosis/prevention & control , Aspergillosis/transmission , Candidiasis, Invasive/diagnosis , Candidiasis, Invasive/drug therapy , Candidiasis, Invasive/epidemiology , Candidiasis, Invasive/etiology , Candidiasis, Invasive/prevention & control , Candidiasis, Invasive/transmission , Cohort Studies , Cross Infection/diagnosis , Cross Infection/drug therapy , Cross Infection/epidemiology , Cross Infection/etiology , Cross Infection/prevention & control , Cryptococcosis/diagnosis , Cryptococcosis/drug therapy , Cryptococcosis/epidemiology , Cryptococcosis/etiology , Cryptococcosis/prevention & control , Cryptococcosis/transmission , Drug Interactions , Fungemia/diagnosis , Fungemia/drug therapy , Fungemia/epidemiology , Fungemia/prevention & control , Fungemia/transmission , Humans , Immunocompromised Host , Incidence , Opportunistic Infections/diagnosis , Opportunistic Infections/drug therapy , Opportunistic Infections/epidemiology , Opportunistic Infections/etiology , Opportunistic Infections/prevention & control , Organ Transplantation/adverse effects , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/epidemiology , Postoperative Complications/prevention & control , Practice Guidelines as Topic , Premedication , Risk
6.
Early Hum Dev ; 88 Suppl 2: S60-4, 2012 May.
Article in English | MEDLINE | ID: mdl-22633517

ABSTRACT

BACKGROUND: Fungal colonisation by Candida spp. affects a high proportion of VLBW neonates in NICU. However, few data are available on the clinical characteristics of colonisation in preterm infants who are colonised at baseline via vertical transmission, compared to preterms who become colonised during their stay in NICU via horizontal transmission. MATERIAL AND METHODS: We reviewed the database of a multicentre, randomised trial of prophylactic fluconazole in VLBW neonates conducted in 8 Italian NICUs in the years 2004 and 2005 (Manzoni et al., NEJM 2007;356(24):2483-95). Per the protocol, all enrolled infants underwent weekly surveillance cultures from birth till discharge. We investigated the frequency of the two different modalities of Candida colonisation in this population, as well as the clinical and outcome characteristics possibly related to them. RESULTS: Overall, Candida colonisation affected 54 of 336 infants (16.1%). Baseline (i.e., detected <3(rd) day of life) colonisation affected 16 (4.7%), and acquired 38 (11.4%), of the 54 colonised preterms. Infants with baseline colonisation had significantly higher birth weight (1229 ± 28 g vs. 1047 g ± 29, p = 0.01) and gestational age (30.2 wks ± 2.7 vs. 28.5 wks ± 2.6, p = 0.01), and were significantly more likely to limit progression from colonisation to invasive Candida infection when fluconazole prophylaxis was instituted (21.6% vs. 42.7%, p = 0.009). Isolation of C. parapsilosis was significantly more frequent in infants with acquired colonisation. CONCLUSIONS: Infants with baseline and acquired colonisation differ for demographics characteristics and for their response to fluconazole prophylaxis. This information may be useful for targeting more accurate management strategies for these two different groups of colonised preterms in NICU.


Subject(s)
Antifungal Agents/therapeutic use , Candidiasis, Invasive/drug therapy , Candidiasis, Invasive/prevention & control , Fluconazole/therapeutic use , Infant, Premature, Diseases/drug therapy , Infant, Premature, Diseases/prevention & control , Candida/drug effects , Candida/isolation & purification , Candida/pathogenicity , Candidiasis, Invasive/transmission , Female , Humans , Infant , Infant, Newborn , Infant, Premature , Infant, Very Low Birth Weight , Infectious Disease Transmission, Vertical , Intensive Care Units, Neonatal , Male , Premature Birth
SELECTION OF CITATIONS
SEARCH DETAIL
...